Company intelligence / Profile preview
Micreos
The Hague, South Holland, Netherlandsmicreos.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Micreos is advancing engineered endolysin therapeutics as targeted alternatives to antibiotics, with preclinical data supporting selective killing of pathogenic bacteria while sparing the healthy microbiome. The lead program for atopic dermatitis is entering clinical trials in 2025. Consumer products under the Gladskin brand have already reached hundreds of thousands of users in Europe and the USA, showing significant impact on inflammatory skin conditions such as acne, eczema, and rosacea.
- Therapeutic areas
- OncologyEndocrinologyDermatologyInfectious Diseases
- Modalities
- Recombinant proteinsEngineered endolysinsBacteriophage technology
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Northway Biotech CDMOETH Zürich academic collaboration
Beyond the preview
Go deeper on Micreos.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Micreos.